Paget’s Disease of Bone (PDB) Therapeutics – Pipeline Assessment and Market Forecasts to 2018

Dec. 9, 2011 - PRLog -- GlobalData’s analysis estimated the Paget’s disease of Bone (PDB) therapeutics market to be worth $230.70m in 2010. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 5.3% to reach $148.68m by 2018. This decline is primarily attributed to the decreasing prevalence of PDB which will eventually lead to a decline in the drug treated population. The scheduled patent expiries of Reclast, Fosamax, Miacalcin and Actonel are expected to further affect the PDB market by leaving it vulnerable to generics.

GlobalData analysis shows that the PDB therapeutics market has a moderate level of unmet need because the currently marketed drugs are successful in meeting patient requirements. The currently prescribed drugs are primarily used to alleviate symptoms and prevent disease progression. Although the treatment arena still lacks molecules capable of providing a permanent cure, usage of the approved drugs have yielded beneficial therapeutic outcomes. The unmet need in terms of safety and efficacy in this market is low because bisphosphonates are not known to cause any major adverse events if the dosing schedule is appropriately adhered to. The clinical unmet need is therefore likely to remain unaltered, although there is a possibility that it will increase as no new drugs are expected to enter the market in the next few years. Reports suggest that patients are likely to elicit a weaker pharmacological response to drugs following prolonged exposure. As a result, higher doses or drugs with novel mechanism of action will be required to elicit a response in certain groups of patients. As no new molecules are expected to be launched in the near future, an increase in the clinical unmet need can also be expected.

The current competition in the PDB market is strong with seven approved drugs. The US patents of Reclast, Actonel and Miacalcin are scheduled to expire in 2013, 2014 and 2015 respectively and the European patents covering Reclast and Fosamax are scheduled to expire in 2013 and 2018 respectively, leaving the market vulnerable to generics. These circumstances will result in a decline in the net revenues of the PDB therapeutics market and a more intense market share war.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx...

GlobalData’s analysis shows that the PDB developmental pipeline is weak with only one molecule in Phase II. The pipeline is devoid of disease modifying therapies and oral gallium, the only pipeline molecule, is being developed to alleviate symptoms and prevent disease progression. As oral gallium is currently in Phase II, it is not expected to impact the market during the forecast period.

GlobalData, the industry analysis specialist, has released its new report, “Paget’s Disease of Bone (PDB) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global PDB therapeutics market. The report identifies the key trends shaping and driving the global PDB therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PDB therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Pagets-D...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.